Oncotelic Therapeutics Highlights CEO's Patent Portfolio and Clinical Pipeline Progress

Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an update on its pipeline while recognizing the contributions of Chairman and CEO Dr. Vuong Trieu. Dr. Trieu has filed more than 500 patents and holds 75 issued patents spanning biologics, small molecules, nanoparticles and diagnostics. He co-invented and developed Abraxane (nab-paclitaxel), acquired by Celgene in a $2.9 billion transaction, and later sold Cynviloq (nanoparticle paclitaxel) to NantPharma in a $1.3 billion deal.

The company's mission focuses on addressing high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. Beyond its internal programs, Oncotelic also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics.

Dr. Trieu's career achievements extend across multiple therapeutic areas with a focus on advancing first-in-class treatments for high unmet medical needs. His extensive patent portfolio and successful track record in drug development provide significant validation for Oncotelic's research and development capabilities. The company benefits from the robust portfolio of inventions created by its CEO, who has filed over 150 patent applications and holds 39 issued U.S. patents specifically related to the company's work.

The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. This announcement matters because it demonstrates the strong intellectual property foundation and experienced leadership behind Oncotelic's clinical development programs, which could potentially lead to breakthrough treatments for difficult-to-treat cancers and rare diseases. The company's strategic approach through both internal development and joint ventures positions it to advance multiple therapeutic candidates simultaneously.